New Alzheimer's drug gives patients hope

Donanemab and its precursor, lecanemab, "appear to help people with mild cognitive impairment," a UW Medicine neurologist said. April 25, 2025

Media Contact: Susan Gregg - 206-390-3226, sghanson@uw.edu

UW Medicine’s Memory & Brain Wellness Center recently started treating patients with donanemab, an Alzheimer’s drug. The drug is similar to lecanemab, which the center began offering in late 2023.

Although the drugs cannot cure Alzheimer’s or reverse memory loss, they have been shown to slow the rate of cognitive decline in patients with mild impairment or mild dementia due to Alzheimer’s disease.

Read our related news release. Download broadcast-ready soundbites and related multimedia.

New Alzheimer's drug gives patients hope

New Alzheimer's drug gives patients hope

Suicide prevention among college athletes

Open windows pose danger to toddlers in summer

Para-athlete inspires other athletes with disabilities